BioPharmSignal logoBioPharmSignal

Biotech News

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Apellis Pharmaceuticals (APLS)Apellis PharmaceuticalsCompany update

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were

Related news

BCRXBioCryst Pharmaceuticals2026-06-12 11:00 EST

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

BCRXBioCryst Pharmaceuticals2026-05-27 11:00 EST

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

ARWRArrowhead Pharmaceuticals2026-05-26 14:00 EST

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

CLDXCelldex Therapeutics2026-06-14 14:21 EST

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

REGNRegeneron Pharmaceuticals2026-07-31 11:00 EST

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-07-27 15:00 EST

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

View all latest news

Apellis Pharmaceuticals

Complement C3 Biology Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases. SYFOVRE SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for...

Recent company news

APLSApellis Pharmaceuticals2026-03-31 10:59 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLSApellis Pharmaceuticals2026-03-02 12:00 EST

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

APLSApellis Pharmaceuticals2026-02-24 12:05 EST

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-02-23 12:00 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

APLSApellis Pharmaceuticals2026-02-19 12:00 EST

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Stock data

Close
41.03 USD
Market cap
5.25B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States